Alkermes plc.
ALKS
DELAYED 1 MONTH
22 insider filings · Latest: Jun 4, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jun 4 9:00 PM | David Joseph GaffinEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43.05 | $87.6K | 229,524(D) | View → |
| Jun 1, 2026 | Jun 1 11:26 PM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $41.67 | $375.0K | 77,389(D) | View → |
| May 29, 2026 | May 29 10:03 PM | Samuel Joseph ParisiVP, Finance (Interim PAO) | Sale | 16,217 | $42.36 | $687.0K | 7,717(D) | View → |
| May 4, 2026 | May 5 12:42 AM | David Joseph GaffinEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $33.20 | $67.5K | 231,558(D) | View → |
| May 1, 2026 | May 2 1:05 AM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $33.40 | $300.6K | 81,389(D) | View → |
| Mar 2, 2026 | Mar 5 1:19 AM | Samuel Joseph ParisiVP, Finance (Interim PAO) | Sale | 6,890 | $29.29 | $201.8K | 7,717(D) | View → |
| Mar 2, 2026 | Mar 5 1:18 AM | Christian Todd NicholsSVP, Chief Commercial Officer | Sale | 6,000 | $30.00 | $180.0K | 109,769(D) | View → |
| Mar 2, 2026 | Mar 5 1:16 AM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $29.72 | $267.5K | 89,389(D) | View → |
| Mar 3, 2026 | Mar 5 1:15 AM | David Joseph GaffinEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.76 | $60.5K | 235,626(D) | View → |
| Mar 2, 2026 | Mar 5 1:15 AM | David Joseph GaffinEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.29 | $59.6K | 237,660(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | May 2 1:05 AM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Option Exercise | 5,000 | $19.34 | 11,356(D) | View → |
| Mar 2, 2026 | Mar 5 1:21 AM | Joshua ReedSVP, Chief Financial Officer | Grant/Award | 97,284 | $30.25 | 30,854(D) | View → |
| Mar 2, 2026 | Mar 5 1:20 AM | POPS RICHARD FDirector, Director and CEO, Alkermes plc | Grant/Award | 88,843 | — | 88,843(D) | View → |
| Mar 2, 2026 | Mar 5 1:19 AM | Samuel Joseph ParisiVP, Finance (Interim PAO) | Grant/Award | 29,209 | $30.25 | 14,176(D) | View → |
| Mar 2, 2026 | Mar 5 1:18 AM | Christian Todd NicholsSVP, Chief Commercial Officer | Grant/Award | 97,284 | $30.25 | 30,854(D) | View → |
| Mar 2, 2026 | Mar 5 1:17 AM | Blair Curtis JacksonEVP, Chief Operating Officer | Grant/Award | 138,978 | $30.25 | 44,078(D) | View → |
| Mar 2, 2026 | Mar 5 1:16 AM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Grant/Award | 121,605 | $30.25 | 38,568(D) | View → |
| Mar 2, 2026 | Mar 5 1:16 AM | Craig C. HopkinsonEVP R&D, Chief Medical Officer | Option Exercise | 5,000 | $19.34 | 21,356(D) | View → |
| Mar 2, 2026 | Mar 5 1:15 AM | David Joseph GaffinEVP, CLO, Alkermes, Inc. | Grant/Award | 114,656 | $30.25 | 36,364(D) | View → |
← Previous
Page 2 of 2